Combining metformin with an anti-PD-1 treatment directly activates CD8+ T cells and boosts IFN-γ secretion, leading to the decreased glycolysis and OXPHOS of tumor cells compared with anti-PD-1 treatment alone (91). Here, PDCD1 is linked to neoplasm.